Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2021
Chinook Therapeutics (Nasdaq: KDNY) announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference on July 15, 2021, at 12:00 pm ET. Interested investors can access the live webcast and an archived recording on Chinook's website, available for 30 days. Chinook is focused on developing precision medicines for kidney diseases, with its lead program, atrasentan, in phase 3 trials for IgA nephropathy. The company is also advancing BION-1301 and CHK-336 for various kidney disorders, utilizing innovative research approaches.
- None.
- None.
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 12:00 pm ET.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 30 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
Contact:
Noopur Liffick
Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
media@chinooktx.com
FAQ
When is Chinook Therapeutics participating in the William Blair Biotech Focus Conference?
How can I access the webcast of Chinook Therapeutics' fireside chat?
What are the main products being developed by Chinook Therapeutics?
What is the focus of Chinook Therapeutics in the biopharmaceutical sector?
What phase is atrasentan currently in for kidney disease treatment?
